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Abstract
Background: Cardiac manifestations of neonatal lupus include an array of structural and conduction abnormalities
due to placental transference of maternal anti-SSA/Ro and anti-SSB/La autoantibodies. Late-onset neonatal lupus
cardiomyopathies, occurring outside the neonatal period, is an infrequently reported manifestation with unknown
pathophysiology and poorly defined treatment regimens. Due to the rarity of this condition, additional studies and
case reports are required to better understand and manage late-onset neonatal lupus cardiomyopathies.
Case presentation: A 4-week-old female, born to a mother with known anti-SSA/Ro and anti-SSB/La autoantibodies,
presents with classic cutaneous manifestations for neonatal lupus and is found to have left bundle branch block, severely
dilated cardiomyopathy with an ejection fraction of 25%, and a thin echogenic dyskinetic ventricular septum. Weekly
second trimester and 30-week fetal echocardiograms showed no signs of structural or conduction abnormalities. There
were no histologic signs of inflammation on cardiac tissue biopsy. After a complicated hospital course, she was
successfully treated with biventricular pacemaker, intravenous immunoglobulin, and plasmapheresis.
Conclusions: We present a case of late-onset neonatal lupus with severe dilated cardiomyopathy, a dyskinetic ventricular
septum, and left bundle branch block. To our knowledge, the dyskinetic ventricular septum has never been reported and
left bundle branch block is rarely reported in NL. This case further validates the need for long term cardiac follow up for
patients born with NL, even if lacking cardiac manifestations in the peripartum period. We characterize a unique
presentation of a rare clinical entity, highlighting the diagnostic challenges, and describe a successful treatment course.
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Background
Neonatal lupus (NL) is caused by placental transfer of
maternal anti-Sjögren’s-syndrome type A/Ro (anti-SSA/
Ro) and anti-Sjögren’s-syndrome type B/La (anti-SSB/
La) autoantibodies. The incidence of NL in newborns
who have mothers with positive anti-SSA/Ro and anti-
SSB/La autoantibody titers is approximately 1–2% [1–3].
Cutaneous and cardiac disease are the predominant
manifestations [1, 4]. Conduction defects are the most
common cardiac manifestation in NL with atrioventricu-
lar block (AVB) constituting the principle diagnosis [5].
Approximately 20% of cases develop diffuse cardiac dis-
ease most often manifesting as systolic dysfunction, ven-
tricular dilation, and endocardial fibroelastosis (EFE) [6,
7]. Cardiac manifestations of NL typically occur in utero
or within the neonatal period. However, delayed onset
dilated cardiomyopathy beyond the neonatal period
rarely has been reported [8–12]. Hypotheses suggest this
rare presentation of NL-cardiomyopathy, defined as
“late-onset,” results from a different mechanism com-
pared to the cardiomyopathies occurring in utero or
during the neonatal period [8, 9]. Management of NL-
related cardiomyopathies has been challenging, often
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leading to heart transplant or poor outcomes despite
pacemaker placement [6, 7, 11, 13]. Intravenous im-
munoglobulin (IVIG), corticosteroids, and plasmapher-
esis have been attempted with varying degrees of success
for NL-related cardiomyopathies, but selection of ther-
apy remains difficult due to the small number of re-
ported cases [6, 12, 14]. We present a unique case of NL
with severe dilated cardiomyopathy, a dyskinetic ven-
tricular septum, and left bundle branch block (LBBB).
Our case has conduction manifestations rarely reported,
LBBB, and structural abnormalities never reported, dys-
kinetic ventricular septum. Lastly, we describe successful
treatment with biventricular pacemaker, IVIG, and
plasmapheresis.
Case presentation
A 4-week-old female presented to the dermatology clinic
with a 2-week history of erythematous annular lesions
on the chest, abdomen, lower back, and bilateral poster-
ior auricular regions consistent with NL (Fig. 1).
The 31-year-old mother, who is gravida 2, para 2,
abortus 0 after delivery of the case-patient, has a history
of systemic lupus erythematosus (SLE) and Sjögren syn-
drome with known anti-SSA/Ro and anti-SSB/La auto-
antibodies. She was diagnosed with SLE 7 years ago at
18 weeks gestation during her first pregnancy with her
son. Her son, born at term, did not develop NL and is
currently healthy with mild asthma. She has not seen a
rheumatologist since her first pregnancy and takes no
medications for SLE. There is no known or documented
major organ involvement. She did not receive prenatal
rheumatologic care or medications for SLE during her
pregnancy with the case-patient. The mother retrospect-
ively reported a self-limiting flare of arthritis in the last
2 weeks of the pregnancy. Maternal anti-SSA/Ro and
anti-SSB/La autoantibody levels were not obtained dur-
ing her second pregnancy. Weekly second trimester and
30-week fetal echocardiograms showed no structural ab-
normalities or bradycardia. There was no evidence of
fetal 3rd degree AVB and the ventricular function was
normal. The patient was born via an uncomplicated va-
ginal delivery at term weighing 3450 g with APGAR
scores of 8 and 9 at 1 and 5min, respectively. The new-
born and mother were discharged to home after 24 h
without any concern for NL or other medical conditions.
The patient initially did well with appropriate weight
gain and no cyanosis, shortness of breath, or diaphoresis
when feeding. The cutaneous findings, starting at 2
weeks of life, led to a screening electrocardiogram at 4-
weeks of life which showed LBBB (Fig. 2). Echocardiog-
raphy at 5 weeks of life revealed severely dilated cardio-
myopathy with an ejection fraction of 25%, a thin
echogenic dyskinetic ventricular septum, normal appear-
ing origins of coronary arteries, mild tricuspid insuffi-
ciency, and mild mitral insufficiency (Fig. 3). Despite
adequate weight gain and no symptoms other than the
rash, the patient was admitted for further workup and
medical management of her heart failure.
Initial blood testing confirmed the diagnosis of NL by
revealing an antinuclear antibody titer of 1:640 (normal
value: less than 1:80) and robust anti-SSA/Ro and anti-
SSB/La autoantibody levels greater than 8 enzyme-
linked immunosorbent assay (ELISA) units (normal
value: less than 1 ELISA unit). Screening for lysosomal
acid alpha-glucosidase deficiency (Pompe disease), mus-
cular dystrophies, Barth syndrome, fatty acid oxidation
disorders, mitochondrial disorders, congenital disorders
of glycosylation, mucopolysaccharidoses, and a cardio-
myopathy genetic screening panel (a molecular evalu-
ation for hereditary causes of cardiomyopathy; screening
for abnormalities in over 100 known genes) were all
negative. Cardiac enzymes and screening for viral patho-
gens was not obtained. She was started on heart failure
management consisting of aspirin, captopril, furosemide,
and carvedilol. LBBB persisted but no AVB was detected
during the hospital stay. The patient was discharged on
day 5 with stable hemodynamics and a plan to further ti-
trate the heart failure medications as tolerated.
Two-month and 3-month follow up echocardiography
were unchanged from her first study. She was admitted
Fig. 1 Erythematous annular lesions on the chest and abdomen of
the patient, typical of neonatal lupus dermatitis
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at 3-months of age for intermittent tachypnea and dia-
phoresis with feeding. Frequent non-sustained atrial
tachycardia was discovered, and she was started on di-
goxin. Due to her persistent myopathy, and the unusual
appearance of her thin, echobright, dyskinetic ventricular
septum, she was taken to the cardiac catheterization
laboratory to assess for other possible causes of perinatal
infarction. Cardiac catheterization revealed unremark-
able, patent coronary arteries. Endomyocardial biopsy of
the right ventricle obtained during catheterization re-
vealed no significant histologic abnormalities or antibody
deposition. During catheterization, the patient developed
Fig. 2 Electrocardiogram at 4-weeks of age showing left bundle branch block
Fig. 3 Echocardiography at 5 weeks of life showing severely dilated left ventricle (LV) and thin echogenic, dyskinetic ventricular septum (*). The
origins of coronary arteries were normal with an ejection fraction of 25%, mild tricuspid insufficiency, and mild mitral insufficiency
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bradycardia which was non-responsive to epinephrine
and led to pulseless electrical activity requiring 44 min
of emergent resuscitation and extracorporeal membrane
oxygenation (ECMO). During the subsequent cardiovas-
cular intensive care unit stay, repeat anti-SSA/Ro and
anti-SSB/La autoantibodies at 3 months of life were 4.7
ELISA units and greater than 8 ELISA units, respect-
ively. A biventricular pacemaker was placed at 3 months
and 12 days of life which converted the LBBB to a
narrow complex paced rhythm with significant improve-
ment in septal dyskinesia and stroke volume. Plasma-
pheresis at 3 months and 13 days of life resulted in a
decrease of anti-SSA/Ro and anti-SSB/La autoantibody
from 2.4 ELISA units and 5.2 ELISA units to 0.1 ELISA
units and 1.3 ELISA units, respectively. At 3 months and
14 days of life one dose of IVIG 1 g/kg was given, and
the patient was successfully weaned off ECMO after 7
days of therapy (lasting from 3months and 8 days to 3
months and 14 days of life). Subsequent echocardiog-
raphy 6 days after stopping ECMO revealed improved
systolic function with an ejection fraction of 30%. She
was medically optimized and discharged on captopril, di-
goxin, carvedilol, furosemide, and aspirin.
At 8 months of age, approximately 4 months after dis-
charge, she had a narrower LBBB (QRS duration 100
msec) paced rhythm with her biventricular pacemaker
working appropriately. Echocardiography revealed nor-
mal left ventricular volume and systolic function (ejec-
tion fraction 70%), and furosemide and aspirin were
discontinued. She has remaining neurologic complica-
tions from the emergent resuscitation; however, she is
starting to achieve milestones and has reestablished an
appropriate weight and height percentile for her age.
Discussion and conclusions
Cardiac structural abnormalities, such as dilated cardio-
myopathy and valvular disorders, are well-reported se-
quelae of NL, yet this patient’s thin, dyskinetic
ventricular septum is a structural abnormality which has
not been reported in association with NL [13, 15]. Cor-
onary catheterization was performed to assess for evi-
dence of perinatal infarction of the septum, possibly
related to antibody-mediated coronary artery inflamma-
tion. The coronary catheterization revealed no abnor-
malities, and the endomyocardial biopsy showed no
signs of inflammation, antibody reaction, or infarction.
The etiology of the dyskinetic septum is not well-
defined; however, it is likely similar to the underlying
pathology leading to the patient’s dilated cardiomyop-
athy. Endomyocardial biopsies in NL-related dilated car-
diomyopathy are often associated with immunoglobulin
deposition and other inflammatory signs [4, 13]. How-
ever, there are reports of anti-SSA/Ro and/or anti-SSB/
La positive patients with dilated cardiomyopathy who
are found to have biopsies negative for inflammation or
immunoglobulin deposition [8, 10–12]. Morel et al. pro-
posed a distinct subtype of NL-related postnatal dilated
cardiomyopathy [8]. This subtype is defined as “late-on-
set” and lacks histologic evidence of inflammation or im-
mune deposits. Morel et al. suggested the later onset of
clinically significant cardiomyopathy is precipitated by
an unknown postnatal factor, possibly related to a virus
or pacemaker placement (in those patients with AVB).
Estimates for median age of onset of late-onset dilated
cardiomyopathy include 11.5 months (range: 14 days to
9.3 years) and 15.2 months (range: 3.6 months to 22.8
years) [8, 11, 12]. In these reported cases, spontaneous
development of dilated cardiomyopathy with marked re-
duction in ejection fractions occurred in patients who
previously had either mild clinical findings of NL (char-
acteristic of our patient) or required perinatal pacemaker
placement. Given our patient’s benign fetal echocardiog-
raphy, her structural defects associated with negative
histologic findings may be related to this same “late-on-
set” process. Lastly, the reported timeline for median age
of onset of late-onset dilated cardiomyopathy warrants
long term follow up in patients born with NL, even if
lacking cardiac manifestations in the peripartum period.
The lack of histologic immunoglobulin deposition,
which has been reported in late-onset dilated cardiomy-
opathy, creates a challenge to definitively explain an eti-
ology. The most common cause of pediatric dilated
cardiomyopathy is idiopathic (approximately 66% of the
cases), while frequently identified causes are related to
myocarditis, neuromuscular disorders, familial cardiomy-
opathies, errors in metabolism, and congenital malfor-
mations [16]. Neuromuscular disorders, such as
muscular dystrophies, and errors in metabolism, such as
Pompe disease, were ruled out. The patient has no
known family history of heart disease so familial cardio-
myopathy is not likely. There were no viral prodromal
symptoms prior to presentation and endomyocardial bi-
opsy was negative for any signs of infective myocarditis.
Although we cannot completely rule out the possibility
of a coincidental idiopathic dilated cardiomyopathy,
based on the extensive negative workup, and the pres-
ence of other NL symptoms, we do not suspect this to
be the case. Our patient had classic NL cutaneous find-
ings, high anti-SSA/Ro and anti-SSB/La titers, electro-
conductive pathology, and cardiomyopathy – all unifying
sequelae well-described in NL. The mechanism of late-
onset NL is not yet elucidated, but anti-SSA/Ro and
anti-SSB/La titers are believed to be predictive factors
for developing late-onset dilated cardiomyopathy [8–10].
The annual incidence of pediatric cardiomyopathies in
the United States is 1.1–1.5 cases per 100,000, and the
incidence of pediatric dilated cardiomyopathy is 0.56
cases per 100,000 person years [17, 18]. In contrast, the
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incidence for late-onset dilated cardiomyopathy in pa-
tients with positive anti-SSA/Ro and anti-SSB/La ti-
ters ranges from 5 to 14.9% [8–10, 19]. Lastly, our
patient shares characteristics of other published cases
of late-onset dilated cardiomyopathy in NL with and
without histologic evidence of myocardial inflamma-
tion [8, 10–12].
The classic cardiac manifestation in NL is AVB which
most often occurs with a structurally normal heart [4].
Other arrhythmias and conduction abnormalities have
been reported including sinus node dysfunction, QT
prolongation, and low QRS voltage [5, 13]. Bundle
branch pathology in NL has been infrequently reported,
and we are aware of only 3 other cases of LBBB as de-
scribed by Wang et al. [5, 14, 20]. Of note, the structural
pathology of our patient’s septum could explain or con-
tribute to the LBBB independent of any antibody-
mediated pathology.
It is rare to see structural heart disease in NL in the
absence of AVB, and the incidence of any structural
heart disease is unknown in anti-SSA/Ro and/or anti-
SSB/La positive patients without AVB [4, 13, 21]. Nield
et al. reported the first 3 cases of isolated EFE associated
with anti-SSA/Ro and anti-SSB/La antibodies in the ab-
sence of AVB. The authors suggested a separate patho-
physiologic cardiac manifestation of NL apart from the
process which causes the classic AVB. Immunoglobulin
(Ig) M, IgA, and the occasional B-cell was found in the
cardiac tissue suggesting a secondary ongoing postnatal
autoimmune reaction following the initial maternal
antibody-mediated myocardial damage in utero. This
suggested postnatal process may lead to a variety of
structural changes including EFE and ventricular dilation
[7]. However, our case is unique in that the late onset
structural heart disease occurred in the absence of histo-
logic evidence of inflammation.
The hypothesis of an ongoing postnatal autoimmune
reaction led to the further investigation into a variety of
prenatal and postnatal IVIG and corticosteroid regimens
in patients with autoantibody-mediated fetal cardiomy-
opathies [6]. Trucco et al. demonstrated that IVIG and
corticosteroid treatments showed some promise as 16 of
20 (80%) patients were alive with normal ventricular
function at median follow up of 2.9 years. EFE was the
identified structural abnormality in 16 patients and the
remaining 4 patients had only systolic dysfunction. Of
note, EFE was diagnosed with echocardiography and
there were no confirmatory histologic samples [6]. The
aforementioned Wang et al. manuscript describes 3
cases of NL with LBBB and dilated cardiomyopathy re-
sembling our patient. There was no further description
of cardiac tissue histologic analysis of the 3 patients. The
3 patients were treated with IVIG and glucocorticoids,
did not receive a pacemaker, and are in stable condition
now [14]. Despite the lack of histologic evidence for in-
flammation in our patient, IVIG and plasmapheresis
were utilized. There was some concern for early devel-
opment of EFE so plasmapheresis plus IVIG was thought
to possibly mitigate any developing secondary immune
process. However, the concern for EFE was largely clin-
ical, lacking objective evidence, and IVIG and plasma-
pheresis was initiated partly due to the patient’s critical
status. Pacemaker placement, plasmapheresis, then IVIG
were administered in sequential days leading to im-
provement in ejection fraction in 6 days. It is impossible
to say if IVIG and plasmapheresis provided any
stabilization or if patient’s clinical status would have im-
proved with pacemaker placement alone.
In summary, cardiac structural abnormalities may
present postnatally in NL with or without histologic evi-
dence of inflammation. The cardiac abnormalities may
be delayed beyond the neonatal period necessitating the
need for long term cardiac follow up in NL patients. The
mechanism behind these structural abnormalities is still
unclear. We present a NL case with rare structural and
conduction abnormalities and negative histologic find-
ings. The patient was successfully treated with biventri-
cular pacemaker, IVIG, and plasmapheresis.
Abbreviations
NL: Neonatal lupus; LBBB: Left bundle branch block; AVB: 3rd degree
atrioventricular block; ELISA: Enzyme-linked immunosorbent assay;
ECMO: Extracorporeal membrane oxygenation; IVIG: Intravenous




BR performed the chart review and generated the manuscript. ANH initiated
the project and recruited BR, reviewed all dermatologic findings, and
proofread/modified the manuscript. ESE reviewed all cardiac findings,
prepared the cardiology figures, and proofread/modified the manuscript. All
authors read and approved the final manuscript.
Funding
This manuscript has no funding.
Availability of data and materials
Data and materials can be obtained for review by contacting the
Corresponding Author.
Ethics approval and consent to participate
All procedures performed involving human participants were in accordance
with the ethical standards of the institutional and/or national research
committee and with the 1964 Helsinki declaration and its later amendments
or comparable ethical standards.
This article does not report or involve any studies with animals or plants
performed by any of the authors. Not applicable.
Consent for publication
Written informed consent for publication of their clinic details and/or clinical
images was obtained from the parent of the patient. A copy of the consent
form is available for review by the editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Rumancik et al. BMC Cardiovascular Disorders          (2020) 20:352 Page 5 of 6
Author details
1Indiana University School of Medicine, Indianapolis, IN 46202, USA.
2Department of Dermatology, Indiana University School of Medicine,
Indianapolis, IN 46202, USA. 3Department of Pediatrics, Section of Cardiology,
Indiana University School of Medicine, 705 Riley Hospital Drive, Suite 1134,
Indianapolis, IN 46202, USA.
Received: 12 May 2020 Accepted: 20 July 2020
References
1. Lee LA. The clinical spectrum of neonatal lupus. Arch Dermatol Res. 2009;
301(1):107–10.
2. Lee LA. Neonatal lupus: clinical features and management. Paediatr Drugs.
2004;6(2):71–8.
3. Buyon JP, Clancy RM. Neonatal lupus: basic research and clinical
perspectives. Rheum Dis Clin N Am. 2005;31(2):299–313.
4. Vanoni F, Lava SAG, Fossali EF, et al. Neonatal systemic lupus Erythematosus
syndrome: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):
469–76.
5. AlTwajery M, AlMane W, Al-Mayouf SM. Electrocardiographic disturbances in
children with systemic lupus erythematosus. Int J Pediatr Adolesc Med.
2018;5(4):127–30.
6. Trucco SM, Jaeggi E, Cuneo B, et al. Use of intravenous gamma globulin
and corticosteroids in the treatment of maternal autoantibody-mediated
cardiomyopathy. J Am Coll Cardiol. 2011;57(6):715–23.
7. Nield LE, Silverman ED, Smallhorn JF, et al. Endocardial fibroelastosis
associated with maternal anti-Ro and anti-La antibodies in the absence of
atrioventricular block. J Am Coll Cardiol. 2002;40(4):796–802.
8. Morel N, Levesque K, Maltret A, et al. Incidence, risk factors, and mortality of
neonatal and late-onset dilated cardiomyopathy associated with cardiac
neonatal lupus. Int J Cardiol. 2017;248:263–9.
9. Villain E, Coastedoat-Chalumeau N, Marijon E, Boudjemline Y, Piette JC,
Bonnet D. Presentation and prognosis of complete atrioventricular block in
childhood, according to maternal antibody status. J Am Coll Cardiol. 2006;
48(8):1682–7.
10. Udink ten Cate FE, Breur JM, Cohen MI, et al. Dilated cardiomyopathy in
isolated congenital complete atrioventricular block: early and long-term risk
in children. J Am Coll Cardiol. 2001;37(4):1129–34.
11. Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development
of late-onset cardiomyopathy, a previously underappreciated sequela. J Am
Coll Cardiol. 2001;37(1):238–42.
12. Taylor-Albert E, Reichlin M, Toews WH, Overholt ED, Lee LA. Delayed dilated
cardiomyopathy as a manifestation of neonatal lupus: case reports,
autoantibody analysis, and management. Pediatrics. 1997;99(5):733–5.
13. Hornberger LK, Al RN. Spectrum of cardiac involvement in neonatal lupus.
Scand J Immunol. 2010;72(3):189–97.
14. Wang B, Hu S, Shi D, Bing Z, Li Z. Arrhythmia and/or cardiomyopathy
related to maternal autoantibodies: descriptive analysis of a series of 16
cases from a single center. Front Pediatr. 2019;7:465.
15. Llanos C, Friedman DM, Saxena A, et al. Anatomical and pathological
findings in hearts from fetuses and infants with cardiac manifestations of
neonatal lupus. Rheumatology (Oxford). 2012;51(6):1086–92.
16. Lipshultz SE, Cochran TR, Briston DA, et al. Pediatric cardiomyopathies:
causes, epidemiology, clinical course, preventive strategies and therapies.
Futur Cardiol. 2013;9(6):817–48.
17. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of
dilated cardiomyopathy in children. Jama. 2006;296(15):1867–76.
18. Choudhry S, Puri K, Denfield SW. An update on pediatric cardiomyopathy.
Curr Treat Options Cardiovasc Med. 2019;21(8):36.
19. Lopes LM, Tavares GM, Damiano AP, et al. Perinatal outcome of fetal
atrioventricular block: one-hundred-sixteen cases from a single institution.
Circulation. 2008;118(12):1268–75.
20. Li L, Dong GF, Han FZ, Cui Y, Shi YZ, Zhang X. Neonatal lupus
erythematosus: a report of 7 cases and review of 87 cases of China.
Zhonghua Er Ke Za Zhi. 2011;49(2):146–50.
21. Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, et al. Outcome of
pregnancies in patients with anti-SSA/Ro antibodies: a study of 165
pregnancies, with special focus on electrocardiographic variations in the
children and comparison with a control group. Arthritis Rheum. 2004;50(10):
3187–94.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Rumancik et al. BMC Cardiovascular Disorders          (2020) 20:352 Page 6 of 6
